EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Effect of fezolinetant on sleep disturbance and impairment during treatment of vasomotor symptoms due to menopause

Marla Shapiro C M, Antonio Cano, Rossella E Nappi, Nanette Santoro, Marci L English, Shayna Mancuso, Antonia Morga, Emad Siddiqui, Udaya Valluri, Faith D Ottery

Maturitas · 2024-08 · 186 · 107999

DOI: 10.1016/j.maturitas.2024.107999 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Maturitas, 2024-08. Verfasst von Marla Shapiro C M und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada. Electronic address: MarlaMD@aol.com. Hauptthemen laut MEDLINE: Sleep Wake Disorders, Menopause, Hot Flashes. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To analyse the effect of fezolinetant on patient-reported sleep disturbance and impairment in individuals with vasomotor symptoms (VMS) using pooled data from the SKYLIGHT 1 and 2 studies. STUDY DESIGN: The SKYLIGHT studies were phase-3, double-blind investigations. Individuals (≥40-≤65 years) who were assigned female at birth and seeking treatment of/relief from moderate-to-severe VMS were enrolled. Participants were randomised to receive placebo, fezolinetant 30 mg, or fezolinetant 45 mg during a 12-week treatment period. MAIN OUTCOME MEASURES: Sleep assessments: Patient-Reported Outcomes Measurement Information System Sleep Disturbance - Short Form 8b (PROMIS SD SF 8b), PROMIS Sleep-Related Impairment - Short Form 8a (PROMIS SRI SF 8a), and Patient Global Impression of Change/Severity in SD (PGI-C SD and PGI-S SD). Assessments were completed at baseline (except PGI-C SD), weeks 4 and 12. RESULTS: Overall, 1022 individuals were randomised and took ≥1 dose of study drug. PROMIS SD SF 8b results showed that improvements in sleep disturbance were observed for fezolinetant 30 and 45 mg versus placebo (week 12, least squares [LS] mean differences: -0.6 [95 % confidence interval [CI]: -1.7, 0.4] for 30 mg and -1.5 [-2.5, -0.5] for 45 mg). Similar improvements in sleep impairment were reported using the PROMIS SRI SF 8a (week 12, LS mean differences: -1.1 [95 % CI: -2.1, -0.1] for 30 mg and -1.3 [-2.3, -0.3] for 45 mg). For PGI-C SD at week 12, 33.6 % (98/292 participants) of the placebo group felt much/moderately better versus 40.1 % (110/274) and 51.0 % (154/302) of the fezolinetant 30 mg and 45 mg groups, respectively. For PGI-S SD at week 12, 44.0 % (129/293) of the placebo group had severe/moderate problems versus 41.1 % (113/275) and 36.6 % (111/303) of the fezolinetant 30 mg and 45 mg groups, respectively. The 12-week timeframe for this analysis was limited by the length of the placebo-controlled period. CONCLUSIONS: Fezolinetant had a beneficial effect on four measures of sleep disturbance and impairment following treatment for VMS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sleep Wake DisordersMenopauseHot FlashesHumansFemaleMiddle AgedDouble-Blind MethodAdultAgedPatient Reported Outcome Measures

Stichwörter der Autor:innen

FezolinetantMenopausePROMIS SD SF 8b measureSleep disturbanceSleep impairmentVasomotor symptoms

Autor:innen und Institutionen

  • Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada. Electronic address: MarlaMD@aol.com.
  • Department of Paediatrics, Obstetrics and Gynaecology, University of Valencia - INCLIVA, Valencia, Spain. Electronic address: Antonio.Cano@uv.es.
  • Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy; Research Center for Reproductive Medicine and Gynecological Endocrinology - Menopause Unit, Fondazione Policlinico…
  • Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, CO, USA. Electronic address: Nanette.santoro@cuanschutz.edu.
  • Astellas Pharma Global Development, Northbrook, IL, USA. Electronic address: marci.english@astellas.com.
  • Astellas Pharma Global Development, Northbrook, IL, USA. Electronic address: shayna.mancuso@astellas.com.

Zitieren

APA

Shapiro C M, M., Cano, A., Nappi, R. E., Santoro, N., English, M. L., Mancuso, S., Morga, A., Siddiqui, E., Valluri, U., & Ottery, F. D. (2024). Effect of fezolinetant on sleep disturbance and impairment during treatment of vasomotor symptoms due to menopause. Maturitas, 186, 107999. https://doi.org/10.1016/j.maturitas.2024.107999

Vancouver

Shapiro C M M, Cano A, Nappi RE, Santoro N, English ML, Mancuso S, et al. Effect of fezolinetant on sleep disturbance and impairment during treatment of vasomotor symptoms due to menopause. Maturitas. 2024;186:107999. doi:10.1016/j.maturitas.2024.107999

BibTeX
@article{ShapiroCM2024,
  author = {Shapiro C M, Marla and Cano, Antonio and Nappi, Rossella E and Santoro, Nanette and English, Marci L and Mancuso, Shayna and Morga, Antonia and Siddiqui, Emad and Valluri, Udaya and Ottery, Faith D},
  title = {Effect of fezolinetant on sleep disturbance and impairment during treatment of vasomotor symptoms due to menopause},
  journal = {Maturitas},
  year = {2024},
  volume = {186},
  pages = {107999},
  doi = {10.1016/j.maturitas.2024.107999}
}
Kostenlos starten →